Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Second chance for thyroid eye disease patients: new drug trial targets Non-Responders

NCT ID NCT07438405

Not yet recruiting Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 23, 2026 · Updated 14 times

Summary

This study is for people with thyroid eye disease who did not respond to a previous treatment or whose symptoms returned. It tests a drug called AMG 732 to see if it can reduce eye bulging. About 30 adults will take part, and the main goal is to check for improvement after 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.